Investor Presentation Q1 2022
11
Investor presentation
First three months of 2022
Rare disease sales grew by 3% driven by both North America
Operations and International Operations
Reported Rare disease sales
Growth at CER
DKK
billion
6
3%
9%
10%
Rare disease sales driven by global commercial execution
Rare disease sales growth driven by:
18%
8%
-8%
.
3% growth in North America Operations
.
3% sales growth in International Operations
5
4
3
Rare blood disorders
2
1
Rare blood disorders sales increased by 9%, driven by:
•
NovoSevenⓇ
•
Uptake of launch products EsperoctⓇ and Refixia®
Rare endocrine disorders sales decreased by 8% driven by:
•
North America Operations sales declined by 20%
•
Novo Nordisk is the leading company in the global human
growth disorder market with a value market share of ~36.4%
0
Total1
Rare
blood
Haem.
A
Haem.
B
Novo- !
SevenⓇ
disorders²
Rare
endocrine
disorders³
1 Total includes "Other Rare disease", which consists of primarily Vagifem® and Activelle®: 2 Comprises NovoSeven®, Novo Eight®, Esperoct®, Refixia® and NovoThirteenⓇ; 3 Primarily Norditropin®.
Note: NovoThirteenⓇ is not shown for Rare blood disorders.
Haem. A: Haemophilia A; Haem. B: Haemophilia B; Unless otherwise specified, sales growth is at constant exchange rates
Novo NordiskⓇView entire presentation